Watch FBRX. Know when insiders buy.
One email the day a filing lands. Free.
FBRX
Forte Biosciences, Inc.
No price history available
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
92
PASS · shorts 92
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP —P/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$87.9MNET CASH $27.6M52W —SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$24.6M | −$23.3M | — | -0.97 | −$22.7M | $0 | −$22.7M | Aug 12 |
| Q1 2026 · Mar 31 | — | — | — | −$22.4M | −$22.1M | — | -1.24 | −$18.8M | $0 | −$18.8M | Aug 12 |
| Q4 2025 · Dec 31derived | — | — | — | −$24.6M | −$24.8M | — | -1.45 | −$16.5M | $0 | −$16.5M | Mar 31 |
| Q3 2025 · Sep 30 | — | — | — | −$18.4M | −$17.7M | — | -0.99 | −$14M | $55K | −$14.1M | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$11.6M | −$11.2M | — | -0.96 | −$10.1M | $0 | −$10.1M | Aug 12 |
| Q1 2025 · Mar 31 | — | — | — | −$16.1M | −$15.7M | — | -1.37 | −$10.4M | $61K | −$10.4M | Aug 12 |
| Q4 2024 · Dec 31derived | — | — | — | −$7.4M | −$7.2M | — | 3.18 | −$10M | $31K | −$10M | Mar 31 |
| Q3 2024 · Sep 30 | — | — | — | −$8.6M | −$8.4M | — | -4.54 | −$8.1M | $0 | −$8.1M | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | −$12.8M | −$12.5M | — | -6.78 | −$5.9M | $0 | −$5.9M | Nov 14 |
| Q1 2024 · Mar 31 | — | — | — | −$7.8M | −$7.4M | — | -4.03 | −$6.7M | $6K | −$6.7M | Nov 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$6.4M | −$5.9M | — | -0.95 | −$9M | $17K | −$9M | Mar 28 |
| Q3 2023 · Sep 30 | — | — | — | −$10.2M | −$10M | — | -6.57 | −$9.1M | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$70.7M | −$69.4M | — | -4.71 | −$50.9M | $116K | −$51M | — | — |
| FY2024 · to Dec 31 | — | — | −$36.6M | −$35.5M | — | -12.17 | −$30.7M | $37K | −$30.8M | — | — |
| FY2023 · to Dec 31 | — | — | −$32.5M | −$31.5M | — | -24.92 | −$28.7M | $88K | −$28.8M | — | — |
| FY2022 · to Dec 31 | — | — | −$13.9M | −$13.9M | — | -0.80 | −$8.2M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$21.5M | −$21.7M | — | -1.55 | −$16.7M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$46.3M | −$46.5M | — | -6.32 | −$18.4M | — | — | — | — |
Every number comes from Forte Biosciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.